Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 6/20 | 0.41 |
| ▸ | CES2 | O00748 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 3/20 | 0.32 |
| ▸ | PPARD | Q03181 | 3/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777580 | 0.94 | NAAA (0.47) | NAAACES1CES2ALDH1A1KMT2A | |
| SCHEMBL30484221 | 0.82 | NAAA (0.52) | NAAACES1CES2ALDH1A1TP53 | |
| SCHEMBL3119816 | 0.80 | NAAA (0.61) | NAAACES1CES2ALDH1A1TP53 | |
| SCHEMBL3115794 | 0.73 | NAAA (0.52) | NAAAALDH1A1TP53KMT2AMAPT | |
| SCHEMBL3128515 | 0.72 | NAAA (0.55) | NAAAALDH1A1TP53KMT2AMAPT | |
| SCHEMBL7684249 | 0.71 | — | — | |
| SCHEMBL27757367 | 0.71 | CES1 (0.65) | CES1CES2ALDH1A1TP53KMT2A | |
| SCHEMBL106334 | 0.71 | CES1 (0.65) | CES1CES2ALDH1A1TP53KMT2A | |
| SCHEMBL3120743 | 0.69 | NAAA (0.52) | NAAAALDH1A1TP53KEAP1NFE2L2 | |
| SCHEMBL2124601 | 0.69 | CES1 (0.55) | CES1CES2ALDH1A1TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023096511-A1 | DRUG LIPID CARRIER, PHARMACEUTICAL FORMULATION, USES THEREOF AND METHOD FOR PREPARATION OF DRUG LIPID CARRIER, CARRIER OBTAINED BY THIS METHOD AND USES THEREOF | UNIWERSYTET WARSZAWSKI (PL) | 2023-06-01 | — | — | WO | claimed |
| EP-3846790-A1 | COMBINATION OF ISOTHIOCYANATES WITH ORGANIC SELENIUM COMPOUNDS ENCAPSULATED IN DRUG CARRIERS AS NEW PHARMACEUTICAL AGENTS WITH ANTI-TUMOR ACTIVITY | Narodowy Instytut Leków W Warszawie (PL) | 2021-07-14 | — | — | EP | claimed |
| EP-3843754-A1 | CONJUGATES OF SELENIUM AND ISOTHIOCYANATE NANOPARTICLES FOR USE IN THE TREATMENT OF TUMORS | Narodowy Instytut Leków W Warszawie (PL) | 2021-07-07 | — | — | EP | claimed |
| WO-2020046153-A1 | CONJUGATES OF SELENIUM AND ISOTHIOCYANATE NANOPARTICLES FOR USE IN THE TREATMENT OF TUMORS | NARODOWY INSTYTUT LEKÓW W WARSZAWIE (PL) | 2020-03-05 | — | — | WO | claimed |
| US-7879822-B2 | Stabilized sulforaphane | PHARMAGRA LABS, INC. (US) | 2011-02-01 | — | — | US | claimed |
| EP-3843754-B1 | CONJUGATES OF SELENIUM AND ISOTHIOCYANATE NANOPARTICLES FOR USE IN THE TREATMENT OF BREAST CANCER | NARODOWY INST LEKOW W WARSZAWIE (PL) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023096511-A1 | DRUG LIPID CARRIER, PHARMACEUTICAL FORMULATION, USES THEREOF AND METHOD FOR PREPARATION OF DRUG LIPID CARRIER, CARRIER OBTAINED BY THIS METHOD AND USES THEREOF | UNIWERSYTET WARSZAWSKI (PL) | 2023-06-01 | — | — | WO | disclosed |
| EP-3846790-A1 | COMBINATION OF ISOTHIOCYANATES WITH ORGANIC SELENIUM COMPOUNDS ENCAPSULATED IN DRUG CARRIERS AS NEW PHARMACEUTICAL AGENTS WITH ANTI-TUMOR ACTIVITY | Narodowy Instytut Leków W Warszawie (PL) | 2021-07-14 | — | — | EP | disclosed |
| EP-3843754-A1 | CONJUGATES OF SELENIUM AND ISOTHIOCYANATE NANOPARTICLES FOR USE IN THE TREATMENT OF TUMORS | Narodowy Instytut Leków W Warszawie (PL) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020046153-A1 | CONJUGATES OF SELENIUM AND ISOTHIOCYANATE NANOPARTICLES FOR USE IN THE TREATMENT OF TUMORS | NARODOWY INSTYTUT LEKÓW W WARSZAWIE (PL) | 2020-03-05 | — | — | WO | disclosed |
| US-20160166643-A1 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | THE JOHNS HOPKINS UNIVERSITY | 2016-06-16 | — | — | US | disclosed |
| US-9308192-B2 | Use of NRF2 inducers to treat epidermolysis bullosa simplex and related diseases | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140243267-A1 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| US-20110003747-A1 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-01-06 | — | — | US | disclosed |
| WO-2009014624-A2 | NRF2 INDUCERS FOR TREATING EPIDERMOLYSIS BULLOSA SIMPLEX | JOHNS HOPKINS UNIVERSITY (US) | 2009-01-29 | — | — | WO | disclosed |
| US-5589504-A | Treatment of newborn jaundice | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243267-A1 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | KEAP1, NFE2L2, KRT18 | NAAA 2111/4885CES1 1548/4885CES2 3280/4885 |
| US-20110003747-A1 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | KEAP1, NFE2L2, KRT18 | NAAA 2111/4885CES1 1548/4885CES2 3280/4885 |
| US-20160166643-A1 | USE OF NRF2 INDUCERS TO TREAT EPIDERMOLYSIS BULLOSA SIMPLEX AND RELATED DISEASES | KEAP1, NFE2L2, KRT18 | NAAA 2111/4885CES1 1548/4885CES2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.